• This study provides further evidence of similar efficacy and safety between direct oral anti-Xa inhibitors and warfarin
    in morbidly obese patients with VTE
  • Overall incidence of recurrent VTE and stroke was low in morbidly obese patients prescribed apixaban, rivaroxaban,
    or warfarin; including those with BMI ≥50 kg/m²
  • In patients with VTE, no significant differences were observed between DOAC and warfarin cohorts in bleeding
    events, including major bleeding
  • Although the overall low incidence of events in this study population was reassuring, a randomized controlled trial is
    needed to enable patients with morbid obesity to benefit from more convenient therapies, which might also offer a net
    clinical benefit